Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective alpha-1 adrenergic receptor antagonist that preferentially blocks alpha-1A receptors in the prostate and bladder neck, promoting smooth muscle relaxation and improving urinary flow.
## Primary Indications
* Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsive therapy for ureteral calculi.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily. May increase to 0.8 mg daily after 2–4 weeks if inadequate response is observed.
* **Maximum Dose:** 0.8 mg daily.
* **Administration:** Take 30 minutes after the same meal each day. Swallow capsule whole; do not crush or chew.
## Pediatric Dosing
* **Not indicated/Not established.** Clinical safety and efficacy have not been established in the pediatric population.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment indicated; use with caution in patients with severe renal impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** No dosage adjustment for mild to moderate impairment; use with caution in severe hepatic impairment.
* **CYP3A4 Inhibition:** If used with strong inhibitors (e.g., ketoconazole), clinical caution is required; reduce dose or avoid if necessary.
## Contraindications
* Hypersensitivity to tamsulosin or any component of the formulation.
* History of orthostatic hypotension or syncope.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis, fatigue.
* **Serious:** Orthostatic hypotension (with or without syncope), intraoperative floppy iris syndrome (IFIS) during cataract surgery, priapism (rare), angioedema.
## Key Drug Interactions
* **PDE5 Inhibitors:** Concomitant use (e.g., sildenafil, tadalafil) may result in additive hypotensive effects; initiate at lowest dose.
* **CYP3A4 and CYP2D6 Inhibitors:** Concurrent use with inhibitors (e.g., clarithromycin, paroxetine) may increase tamsulosin plasma concentrations.
* **Antihypertensives:** Potential for additive blood pressure lowering; monitor for symptomatic hypotension.
## Monitoring
* Monitor blood pressure periodically, especially upon initiation or dose escalation.
* Assess symptom improvement (International Prostate Symptom Score - IPSS).
* Screen for prostate cancer prior to initiation of therapy.
## Clinical Pearls
* **Cataract Surgery:** Advise patients to inform their ophthalmologist of current or past tamsulosin use due to the risk of "Intraoperative Floppy Iris Syndrome" (IFIS).
* **First-Dose Syncopy:** Although less common with tamsulosin compared to non-selective alpha-blockers, advise patients to rise slowly from a sitting or lying position.
* **Efficacy:** While 0.4 mg is standard, the 0.8 mg dose provides greater efficacy for some patients but increases the risk of side effects.
***
**Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Always verify dosages, contraindications, and drug interactions against current institutional protocols, prescribing leaflets, and updated clinical guidelines before administration.
